1.Appropriate use of Prostate-Specific Antigen in Diagnosing Carcinoma of the Prostate.
Yun Sik KWAK ; Young Ae LIM ; Hee Sun JEON
Journal of the Korean Geriatrics Society 1997;1(1):12-17
No abstract available.
Prostate*
;
Prostate-Specific Antigen*
2.In Search of a New Prostate-Specific Antigen
International Neurourology Journal 2019;23(1):3-4
No abstract available.
Prostate-Specific Antigen
3.Multicenter Comparison of Four Automated Immunoassay Analyzers for Prostate Specific Antigen
Dong Jin PARK ; Yeongsic KIM ; Hae Kyung LEE ; Jehoon LEE ; Kyungja HAN ; Hi Jeong KWON
Annals of Laboratory Medicine 2019;39(4):406-410
No abstract available.
Immunoassay
;
Prostate
;
Prostate-Specific Antigen
4.The Factors Influencing the Percentage of Free Serum Prostate Specific Antigen Levels in Men without Clinically Detectable Prostate Cance.
Dae Young KIM ; Cheol KWAK ; Seung Bae LEE ; Eun Chan PARK ; Hyeon JEONG ; Sang Eun LEE
Korean Journal of Urology 2000;41(6):718-724
No abstract available.
Humans
;
Male
;
Prostate*
;
Prostate-Specific Antigen*
5.The Factors Influencing the Percentage of Free Serum Prostate Specific Antigen Levels in Men without Clinically Detectable Prostate Cance.
Dae Young KIM ; Cheol KWAK ; Seung Bae LEE ; Eun Chan PARK ; Hyeon JEONG ; Sang Eun LEE
Korean Journal of Urology 2000;41(6):718-724
No abstract available.
Humans
;
Male
;
Prostate*
;
Prostate-Specific Antigen*
6.The Effect on Serum Prostate Specific Antigen after Transurethral Resection of Prostate for Benign Prostate Hypertrophy.
Hee Jong JEUNG ; Bong Ryoul OH ; Jai Dong MOON
Korean Journal of Urology 1997;38(1):70-75
PURPOSE: It is important to know for transurethral resection of prostate (TURP) affecting the serum prostate specific antigen (PSA) value how long one should wait before being able to ~ obtain an accurate and meaningful serum PSA level. We evaluated the change of serum PSA concentration in patients with benign prostate hypertrophy(BPH) before and after TURP in association with time course and resected prostatic weight. MATERIALS AND METHOD: The effect of TURP was examined in 27 patients with BPH (mean age: 64 years; range: 55-79 years). The serum PSA levels were measured serially (before and 1, 3, 5, 7, 14, 30, 60, 90 days after TURP) by Abott IMX assay. RESULTS: The level of serum PSA appeared to be consistent with prostatic volume by transrectal ultrasonography(TRUS) and was elevated by about 0.16 ng/mL for each gram of hyperplastic tissue present (p=0.375, p=0.058). TURP caused an immediate elevation in the serum PSA concentration, with a median increase of 19 ng/mL (p=0.0001). The larger resected group showed a dramatic and statistically significant PSA rise immediately after TURP than the smaller resected group (p=0.023). From the 15 post-operative day, the PSA concentrations continued slightly lower than that of pre-operative day (p=0.0001), and was still decreased on 30 days (p=0.0001). The median time to return to a baseline level of PSA was 30 days (range: 1460 days) after TURP. CONCLUSION: These findings indicate that TURP caused an immediate increase in the serum PSA level, which generally return to stable, baseline level within 30 days. However, because in some patients the serum PSA still remained elevated than upper normal limit after 30 days, it is recommended that a serum PSA determination should be obtained for at least 60 days after TURP.
Humans
;
Hypertrophy*
;
Prostate*
;
Prostate-Specific Antigen*
;
Transurethral Resection of Prostate*
7.The Effect on Serum Prostate Specific Antigen after Transurethral Resection of Prostate for Benign Prostate Hypertrophy.
Hee Jong JEUNG ; Bong Ryoul OH ; Jai Dong MOON
Korean Journal of Urology 1997;38(1):70-75
PURPOSE: It is important to know for transurethral resection of prostate (TURP) affecting the serum prostate specific antigen (PSA) value how long one should wait before being able to ~ obtain an accurate and meaningful serum PSA level. We evaluated the change of serum PSA concentration in patients with benign prostate hypertrophy(BPH) before and after TURP in association with time course and resected prostatic weight. MATERIALS AND METHOD: The effect of TURP was examined in 27 patients with BPH (mean age: 64 years; range: 55-79 years). The serum PSA levels were measured serially (before and 1, 3, 5, 7, 14, 30, 60, 90 days after TURP) by Abott IMX assay. RESULTS: The level of serum PSA appeared to be consistent with prostatic volume by transrectal ultrasonography(TRUS) and was elevated by about 0.16 ng/mL for each gram of hyperplastic tissue present (p=0.375, p=0.058). TURP caused an immediate elevation in the serum PSA concentration, with a median increase of 19 ng/mL (p=0.0001). The larger resected group showed a dramatic and statistically significant PSA rise immediately after TURP than the smaller resected group (p=0.023). From the 15 post-operative day, the PSA concentrations continued slightly lower than that of pre-operative day (p=0.0001), and was still decreased on 30 days (p=0.0001). The median time to return to a baseline level of PSA was 30 days (range: 1460 days) after TURP. CONCLUSION: These findings indicate that TURP caused an immediate increase in the serum PSA level, which generally return to stable, baseline level within 30 days. However, because in some patients the serum PSA still remained elevated than upper normal limit after 30 days, it is recommended that a serum PSA determination should be obtained for at least 60 days after TURP.
Humans
;
Hypertrophy*
;
Prostate*
;
Prostate-Specific Antigen*
;
Transurethral Resection of Prostate*
8.Value of Prostate-Specific Antigen, Total Prostate Volume, Transition Zone Volume and Transition Zone Index as the Predictors of Effective Response for Alpha-blocker (Terazosin) Monotherapy in the Management of Benign Prostate Hyperplasia.
Sang Hyun PARK ; Luck Hee SUNG ; Choong Hee NOH
Korean Journal of Urology 2002;43(10):842-846
PURPOSE: We investigated the efficacy of various parameters by transrectal ultrasonography (TRUS), and PSA levels, as predictors for the effectiveness of alpha-blocker(terazosin) monotherapy. MATERIALS AND METHODS: We evaluated 126 benign prostatic hyperplasic (BPH) patients, who underwent alpha-blocker (terazosin) monotherapy, according to their International Prostate Symptom Score (IPSS), peak flow rate (Qmax), prostate specific antigen(PSA), total prostate volume (TPV), transition zone volume (TZV) and transition zone index (transition zone volume/total prostate volume, TZI) for prediction the response to alpha-blocker (terazosin) monotherapy in men with symptomatic BPH. The patients were categorized into two groups; the good result, and the poor result groups. RESULTS: Following medication with terazosin, the IPSS decreased and the Qmax was significantly increased in all patients. However, according to the patients' subjective satisfaction of the treatment, those in the good result group (64 patients) had smaller TPV and TZV than those in the poor result group (61 patients). There were no significantly differences in PSA and TZI between the two groups. CONCLUSIONS: Terazosin was effective in reducing the symptoms and the improving peak flow rates in symptomatic BPH patients. TPV and TZV correlated significantly with the evaluated parameters in symptomatic BPH patients who underwent alpha-blocker monotherapy.
Humans
;
Hyperplasia*
;
Male
;
Prostate*
;
Prostate-Specific Antigen*
;
Prostatic Hyperplasia
;
Ultrasonography
9.The effect of prazosin as a first-line therapy for the symptomatic benign prostatichypertrophy.
Korean Journal of Urology 1993;34(5):855-859
We evaluated 41 patients with symptomatic benign prostatic hypertrophy who were treated with prazosin alone more than 3 months. Among them, 21 patients( 51.2%) showed improvement of both symptom score and maximal flow rate. There was the similar effectiveness on the patients with acute urinary retention as on the patients without retention. The pretreated prostate volume and prostate specific antigen were not statistically different between the responders and nonresponders.After with drawl of the medication, almost all patients immediately complained of the symptoms worsened again. So, we concluded that the d-blocker can be used as a first-line therapy in selected patients with symptomatic benign prostatic hypertrophy with temporal effect.
Humans
;
Prazosin*
;
Prostate
;
Prostate-Specific Antigen
;
Prostatic Hyperplasia
;
Urinary Retention
10.The Relationship of Cellular Composition of Benign Prostatic Hyperplasia and Prostate-Specific Antigen (PSA) Levels.
Byung Ha CHUNG ; Bong Hyeon LEE ; Sung Joon HONG
Korean Journal of Urology 1996;37(10):1093-1096
The relationship between the serum values of prostate-specific antigen (PSA) and the histologic composition of benign prostatic hyperplasia (BPH) was investigated in 32 symptomatic BPH patients undergoing transurethral resection of the prostate. We evaluated the free and total PSA concentrations by ACS-PSA2 (Ciba-Corning) assay. The stereological analysis was made by computer aided-area densitometry using H & E stained slides to quantify stromal and glandular areas in the resected prostate tissue. The total PSA concentration versus percentage of glandular area (%G) and stromal-glandular ratio (SGR) correlated significantly (p<0.05 for both) whereas the free PSA concentration and free/total PSA ratio did not (p>0.05 for both). These data suggest that total PSA is directly correlated with the histologic composition of the prostate in men with BPH, however, the proportion of free to total PSA was not informative to predict the histology. Thus, pretreatment evaluation of total PSA would be useful as part of an evaluation method of BPH for medical therapy.
Densitometry
;
Humans
;
Male
;
Prostate
;
Prostate-Specific Antigen*
;
Prostatic Hyperplasia*